Drug Profile
Prezalumab - Amgen/AstraZeneca
Alternative Names: AMG-557; B7RP-1 mAb; MEDI-5872Latest Information Update: 06 Nov 2023
Price :
$50
*
At a glance
- Originator Amgen
- Developer Amgen; MedImmune
- Class Antipsoriatics; Monoclonal antibodies
- Mechanism of Action B7-related protein 1 inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cutaneous lupus erythematosus; Psoriasis; Sjogren's syndrome; Systemic lupus erythematosus
Most Recent Events
- 15 Mar 2021 Viela Bio has been acquired and merged into Horizon Therapeutics plc
- 08 Nov 2019 Adverse events, efficacy and immunogenicity data from a phase II trial in Sjogren's syndrome presented at the 83rd American College of Rheumatology and the 54th Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP-2019)
- 26 Apr 2019 Discontinued - Phase-II for Sjogren's syndrome in France, Sweden, United Kingdom, USA (SC) (AstraZeneca pipeline, April 2019)